Sharon Worcester is an award-winning medical journalist for MDedge News. She has been with the company since 1996, first as the Southeast Bureau Chief (1996-2009) when the company was known as International Medical News Group, then as a freelance writer (2010-2015) before returning as a reporter in 2015. She previously worked as a daily newspaper reporter covering health and local government. Sharon currently reports primarily on oncology and hematology. She has a BA from Eckerd College and an MA in Mass Communication/Print Journalism from the University of Florida. Connect with her via LinkedIn and follow her on twitter @SW_MedReporter.
News
ASH preview: Key themes include tackling CAR T obstacles, sickle cell advances, VTE
New findings take aim at CAR T-cell therapy-related obstacles and highlight potential new paths forward.
News
Large population-based study underscores link between gout, CVD event risk
ATLANTA – The relationships between gout and fatal and nonfatal CVD events found in a large population-based health data linkage study in New...
News
SPIRIT-H2H results confirm superiority of ixekizumab over adalimumab for PsA
ATLANTA – Biologic-naive patients with PsA responded better to ixekizumab than to adalimumab for skin and joint symptoms, and at least as well...
News
COAST-X top-line results: Ixekizumab improves nonradiographic axSpA vs. placebo
ATLANTA – Adding ixekizumab to conventional background medications significantly improved the signs and symptoms of nonradiographic axSpA in the...
News
Biologic DMARDs appear as effective in elderly-onset RA as in young-onset RA
ATLANTA – Elderly-onset RA patients have outcomes with bDMARDs similar to those of young-onset patients, but are less likely to receive them.
News
Weekly tocilizumab provides durable benefits for giant cell arteritis patients
ATLANTA – Tocilizumab’s effects in GCA patients proved durable in nearly half of the patients treated weekly during the GiACTA trial and its 2-...
News
B-cell-poor RA responds better to tocilizumab than to rituximab
ATLANTA – B-cell-poor RA patients responded better to tocilizumab than to rituximab in the randomized, phase 4 R4-RA trial, suggesting a potential...
News
Guselkumab improves psoriatic arthritis regardless of prior TNFi use
ATLANTA – Guselkumab, an anti-IL-23p19 monoclonal antibody, showed efficacy versus placebo for active PsA in both biologic-naive and TNFi-treated...
News
A progressive exercise intervention improved AGFR in breast cancer survivors
BARCELONA – A progressive exercise intervention improved the android:gynoid fat ratio – which correlated with...
News
Exercise improved QoL, functioning in breast cancer survivors
BARCELONA – A supervised and adapted exercise program improved quality of life, physical functioning, and strength in breast cancer survivors...
News
Better overall survival with nivolumab vs. chemo for advanced ESCC
BARCELONA –Nivolumab was associated with improved overall survival and a favorable safety profile vs. chemotherapy...
News
Nivolumab benefit for NSCLC persists at 5-year follow-up
BARCELONA – Nivolumab, compared with docetaxel chemotherapy, led to a fivefold improvement in 5-year overall...
News
Immune checkpoint inhibition in SCLC: Modest outcomes, many questions
Immune checkpoint inhibitors have activity in SCLC, but achieving more durable disease control and better survival requires greater understanding...
News
New data further define role of PD-L1 status, immunotherapy in metastatic breast cancer
BARCELONA – PD-L1 status in mTNBC or HER2+ breast cancer appears to identify distinct disease entities with varying likelihood of benefit from...